HBOT Conversations:
Dr. Paul Harch & The Science Behind The Practice
Dr. Paul G. Harch, M.D. has used hyperbaric oxygen therapy to treat more than 100 different conditions, including stroke, dementia, autism, and traumatic brain injury. His goal is to help his patients get their lives back using hyperbaric oxygen therapy.
He is the author of The Oxygen Revolution and is considered an International expert and pioneer in the field of Hyperbaric Oxygen Therapy (HBOT). His informative, and comprehensive guide on HBOT has helped countless souls better understand what HBOT is and how it directly affects the body at the genetic level.
This episode on The Science Behind the Practice is the fourth in a nine episode series that will be released weekly with Dr. Harch.
Watch the Podcast
di Girolamo asks Dr. Harch to explain his background, and the road he had to take to get to where he is today.
In Episode 4, Dr. Harch tells a miraculous story of how his medical journey with Hyperbaric Oxygen Therapy fell into his lap during his surgical residency. It was during this internship when Dr, Harch was in a horrendous vehicle accident and nearly killed. This led to more than one medical leave of absence. While out on his second leave of absence after yet another surgery, his perspective changed; and he started to wonder what he wanted to do with his life.
After not finding fulfilment in an emergency medicine practice, Dr. Harch decided that he needed to follow his true passion and interest if he was going to have any chance of feeling accomplished, and changing lives.
Dr. Harch had a high level of interest in Navy divers and the extreme cases of brain decompression sickness. He started asking questions about how they were being treated for decompression sickness and why they were not getting better. Dr, Harch refers to the unbelievable cases that landed in his lap as his “Manna from Heaven”. Other doctors tossed these cases to the side, but Dr. Harch decided to try something different with these patients – he treated using lower doses of hyperbaric oxygen therapy. It totally reversed what was going on with these patients!
Even though his results were clinically astonishing, the Medical Societies were surprisingly not impressed or welcoming; forcing Dr. Harch to create more research documentation and do more clinical work to prove his success with hyperbaric oxygen therapy to treat chronic brain issues. During his journey to prove the results, he was implemental in successfully being able to show brain decompression illness on imaging. The imaging results were so dramatic after hyperbaric oxygen therapy that the radiologists didn’t even know how to read it! This is about the time when Dr. Harch’s road to patient care took a straight-shot towards healing a larger variety of indications with HBOT.
His goal today is the same as it was back then…. prove to everyone that Hyperbaric Oxygen Therapy WORKS! Dr. Harch has no plans to retire and stresses that he wants to see this all over the finish line.
Dr. Harch has used HBOT to change the lives of children and adults; but it was his own life that was also greatly changed by the power of hyperbarics. Hyperbaric Oxygen Therapy has allowed Dr. Harch to take the elements of oxygen and pressure, & implement them into healing protocols that have now saved countless lives.
Subscribe Now, It’s Free !
Guest
Dr. Paul G. Harch, MD
Dr. Harch initiated and continues to be a private practice that has resulted in the largest case experience in neurological hyperbaric medicine in the world. In this practice, he adapted the concepts of conventional hyperbaric oxygen therapy to wounds in the central nervous system, which spawned the subsequent academic and research practice. Harch HBOT is the best place to receive oxygen therapy treatments, and patients have traveled from more than 50 countries to be treated by Dr. Harch himself.
Harch HBOT – Hyperbaric Oxygen Therapy Clinic
5216 Lapalco Blvd.
Marrero, LA
504-309-4948
hbot@hbot.com
https://hbot.com/
Recent HBOT News
Clinical Trial – Dose and Response of Intrathecal Hydromorphone in Patients Undergoing Cesarean Section at Virginia Commonwealth University Health System
In the United States the incidence of cesarean deliveries have increased over the last
several decades and is currently approximately 30% nationwide. The anesthesia and analgesia
for elective c-sections vary between institutions.
Parturients present a unique challenge for the anesthesiologist as the mother has to care not
only for herself, but also for the newborn postpartum. While intrathecal opioids provide
adequate pain relief, they do so at the cost of bothersome side effects for patients, such as
pruritus and nausea/vomiting.
Intrathecal hydromorphone has started to be explored as a new option for intrathecal
analgesia. A study done by Beatty et al. showed in a retrospective review that 40 mcg of
intrathecal dilaudid was safe and effective as compared to intrathecal morphine for analgesia
after cesarean delivery. Additionally they showed no difference in side effect profiles of
the two medications. Mhyre et al. investigated the use of 100 mcg of intrathecal dilaudid
with hyperbaric bupivacaine in varying dosages for labor analgesia. The results were
inconclusive, but the dosage of hydromorphone was reported to be without adverse effects.
Virginia Commonwealth University Health Systems has successfully instituted the use of
intrathecal morphine with superior analgesia but with undesired side effects, most notably
pruritus. Recent drug shortages of duramorph have prompted investigators to seek alternative
options for post cesarean section analgesia. The investigators are interested in determining
the dose, efficacy, and side effect profile of intrathecal hydromorphone. Although our
institution has never utilized intrathecal hydromorphone for our patient population, it has
been studied at various other institutions where it has been found to be safe and efficacious
with an acceptable side effect profile.
Repeat spinal anesthesia in cesarean section: A comparison between 10 mg and 12 mg doses of intrathecal hyperbaric (0.05%) bupivacaine repeated after failed spinal anesthesia: A prospective, parallel group study.
Abstract: Spinal anesthesia for cesarean section is not a 100% successful technique. At times, despite straightforward insertion and drug administration, intrathecal anesthesia for cesarean section fails to obtain any sensory or motor block. Very few studies and...
Endocan reduces the malign grade of gastric cancer cells by regulating associated protein expression.
Abstract: Endocan, which has been identified to be low expressed in gastric cancer, was found to be positively related to the differentiation level of gastric cancer in vivo and in vitro. In the present study, we aimed to investigate the role of endocan in gastric...